Last updated: September 22, 2023
Sponsor: Ain Shams University
Overall Status: Completed
Phase
3
Condition
Inflammation
Heart Disease
Coronary Artery Disease
Treatment
Colchicine Tablets
Clinical Study ID
NCT06054100
2511
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- male or female
- >18 yrs
- STEMI patients who were successfully treated with PCI.
Exclusion
Exclusion Criteria:
- Pregnant or breast-feeding women or women of childbearing potential.
- Active inflammatory, known malignancy, infectious diseases or current treatment withcorticosteroids or anti inflammatory agents.
- Known hypersensitivity to colchicine or current chronic treatment with colchicine.
- Severe renal failure (estimated creatinine clearance <30ml/min) or hepatic failure (Child Pugh score B or C )
- Cardiac arrest, ventricular fibrillation, cardiogenic shock or previous myocardialinfarction.
- Patients using the following agents: Strong CYP3A4 inhibitors (ritonavir,clarithromycin, ketoconazole, voriconazole, itraconazole), intermediate CYP3A4inhibitors (aprepitant, diltiazem, erythromycin, fluconazole, verapamil), P-gpinhibitor (amiodarone, clarithromycin, erythromycin, azithromycin, ranolazine,verapamil, ketoconazole, itraconazole) and grape fruit juice
Study Design
Total Participants: 88
Treatment Group(s): 1
Primary Treatment: Colchicine Tablets
Phase: 3
Study Start date:
February 01, 2020
Estimated Completion Date:
May 20, 2022
Study Description
Connect with a study center
Ain shams university
Cairo,
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.